Présentation de l'entreprise
DBV Technologies S.A. operates as a clinical-stage biopharmaceutical entity dedicated to the research and development of epicutaneous immunotherapy products within the French market. The company functions within the broader healthcare sector, specifically focusing on the biotechnology industry where innovation in therapeutic delivery methods is paramount. As of the latest reported data, the enterprise possesses a market capitalization of $1.27B, while its annual revenue generated over the trailing twelve months stands at $5.64M. The number of employees is listed as N/A, indicating that specific headcount metrics are not disclosed in the available financial records. These valuation and revenue figures suggest a mid-to-small-cap profile typical of early-stage biotechnology firms, where significant market capitalization often reflects high investor expectations regarding future clinical milestones rather than current profit generation. The substantial disparity between the $1.27B market cap and the modest $5.64M revenue underscores the speculative nature often associated with clinical-stage assets that rely heavily on future product approvals to realize value.
Santé financière
The company reported a revenue of $5.64M for the trailing twelve months, yet it recorded a net income of $-146,947,008 and an EBITDA of $-143,862,000. The substantial gap between the positive revenue of $5.64M and the massive negative net income of $-146,947,008 reveals a cost structure characterized by significant operating expenses, likely driven by clinical trial costs and research development efforts inherent to the biotechnology sector. Free cash flow is reported at $-64,285,000, which indicates that the company is consuming cash reserves to fund its operations and development pipeline rather than generating surplus liquidity from current business activities. The gross margin stands at 100.0%, suggesting that the cost of goods sold is negligible relative to revenue, a common trait in the early phases of pharmaceutical development before commercialization. However, the operating margin is -6984.7% and the profit margin is 0.0%, illustrating that operating expenses far exceed revenue, preventing any bottom-line profitability despite the efficient production costs. The company holds $194.17M in cash against $6.53M in debt, creating a net cash position that significantly outweighs its liabilities. With a debt-to-equity ratio of 3.87, the balance sheet appears leveraged relative to equity, though the high cash balance mitigates immediate solvency risks. The current ratio of 3.67 indicates a robust short-term liquidity position, suggesting the company has ample current assets to cover its short-term obligations. Return on Equity is -149.8% and Return on Assets is -61.4%, metrics that reveal management is currently not generating returns on capital deployed, a standard but risky condition for pre-commercial biotechnology companies burning through their cash reserves.
Évaluation de la valorisation
The trailing P/E ratio is N/A due to losses, while the forward P/E is listed at -81.44, implying that the market is pricing in future earnings that are not yet realized or are expected to remain negative in the near term. The price-to-book ratio is 6.01, which indicates a significant market premium over the company's book value, suggesting investors are willing to pay a high multiple for the intangible assets and potential of the clinical pipeline. The price-to-sales ratio is 225.87, a metric that highlights the high valuation relative to current sales volume, typical for clinical-stage firms where revenue is minimal but future potential is priced in. The EV/EBITDA stands at -33.92, further confirming that traditional earnings-based valuation multiples are not applicable given the negative earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week low of $6.69 and a 52-week high of $26.18, providing a range of $19.49 within which the current price must be situated to assess its relative standing in the trading range. The beta value is -0.20, an anomaly for equity instruments that suggests an inverse correlation to the broader market or indicates extreme volatility and idiosyncratic risk that does not move in tandem with market indices. These valuation metrics collectively paint a picture of a high-risk, high-potential asset where traditional financial ratios offer limited insight into intrinsic value.
Growth & Income
Revenue growth over the past year is recorded at 26.2%, indicating a strong expansion in top-line sales, whereas earnings growth is N/A because the company has not yet achieved profitability. The absence of earnings growth data combined with the positive revenue growth implies that the company is in a growth phase where sales are increasing faster than costs, though absolute earnings remain negative. DBV Technologies S.A. does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available cash flow and reserves directly into research, development, and clinical trials rather than distributing income to shareholders. This non-dividend policy is standard for clinical-stage biotechnology firms that prioritize capital allocation toward product advancement over income generation for investors. The overall growth and income profile reflects a pure-play growth strategy focused on future commercialization potential rather than current income yield or stable earnings.